| Valuation |
9.3 |
auto |
P/E 28.1 |
| Liquidity |
9.9 |
auto |
Current ratio 2.90 |
| Growth |
6.9 |
auto |
Revenue growth 9.5% |
| Profitability |
10.0 |
auto |
Net margin 32.9% |
| Efficiency |
9.3 |
auto |
ROE 22.5% |
| Leadership Tenure |
8.2 |
ai |
CEO Reshma Kewalramani has led since April 2020 (~5 years), with strong continuity from prior CMO role and stable executive bench including CSO David Altshuler; clean post-Leiden transition. |
| Ownership Alignment |
4.3 |
auto |
Insider holding 0.21% |
| Strategic Vision |
9.0 |
ai |
Clear roadmap extending CF monopoly with Vanzacaftor triple, expanding into non-opioid pain (Journavx/suzetrigine FDA approved Jan 2025), sickle cell/beta-thal via Casgevy (first CRISPR therapy approved), APOL1 kidney disease (inaxaplin), and Type 1 diabetes (islet cell therapy). |
| Focus / Clarity |
8.4 |
ai |
Disciplined focus on serial innovation in specialty diseases with high unmet need; CF remains core (~$10B+ revenue) with coherent expansion into adjacent genetic/serious diseases rather than scattershot M&A. |
| Diversification |
6.5 |
ai |
Still heavily dependent on CF franchise (~85%+ of revenue from Trikafta/Kaftrio), but Casgevy, Journavx, and pipeline launches in 2025 are beginning meaningful diversification. |
| Maturity / Revenue |
8.6 |
ai |
Revenue $12.0B |
| Growth Potential |
9.1 |
ai |
Massive forward TAM: non-opioid pain market ($30B+ TAM with Journavx), APOL1 kidney disease, Type 1 diabetes cell therapy (potentially curative), CRISPR platform via Casgevy, plus vanzacaftor extending CF dominance — multiple shots on goal in large markets. |
| Volatility |
5.5 |
auto |
β 0.37 · D/E 10.91 |
| Market Standing |
8.7 |
auto |
Market cap $109.4B |
| Competitive Moat |
9.2 |
ai |
Effective monopoly in cystic fibrosis (>90% addressable share, no competing modulators), first-mover CRISPR commercialization with Casgevy partnership, first-in-class Nav1.8 mechanism in pain, R&D >20% of revenue — stacks IP, regulatory exclusivity, and scientific leadership. |